MDL Track
MDL 3043
S.D.N.Y.
Acetaminophen ASD/ADHD products liability
58 pending
Pharmaceutical · claims focused on acetaminophen exposure and alleged developmental injuries
Defendant
Johnson & Johnson Consumer Inc.
MDL / Track
MDL 3043
S.D.N.Y.
Judge
Judge Denise L. Cote
Plaintiffs
~74 pending (58 per JPML March 2, 2026 report, plus ~16 new filings tracked since)
Bellwether / Trial
No verdicts yet
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
The Second Circuit on July 14, 2026 reversed Judge Denise Cote's exclusion of three plaintiffs' general causation experts in In re: Acetaminophen ASD/ADHD Products Liability Litigation, MDL No. 22-3043 (S.D.N.Y.), reviving nearly 600 federal lawsuits alleging prenatal acetaminophen exposure causes autism and ADHD. The panel held Cote exceeded her gatekeeping authority under Daubert in striking Harvard School of Public Health Dean Andrea Baccarelli and two others, while affirming exclusion of two additional experts and rejecting federal preemption of failure-to-warn claims. Texas Attorney General Ken Paxton filed a parallel state enforcement action in October 2025 (Texas v. Johnson & Johnson and Kenvue, Panola County District Court) alleging DTPA violations and fraudulent transfer of Tylenol liabilities.
Causation Theory
Plaintiffs' causation theory rests on epidemiological studies finding associations between prenatal acetaminophen exposure and neurodevelopmental disorders, including a 2019 Johns Hopkins Bloomberg School study and a 2021 Nature Reviews Endocrinology consensus statement. Biological mechanism theories propose acetaminophen may interfere with endocrine signaling during fetal brain development. The FDA concluded in 2023 that available evidence was "unable to support a determination of causality." HHS Secretary Robert Kennedy issued public health warnings in September 2025 cautioning pregnant women against acetaminophen use.
Case Management Orders
Litigation status
The Second Circuit reversed Judge Denise Cote's Daubert exclusion of three plaintiff general causation experts on July 13, 2026, reviving MDL 3043 (In re: Acetaminophen ASD/ADHD Products Liability Litigation, 1:22-md-03043) in the S.D.N.Y. Judge Guido Calabresi's 64-page opinion held Cote overstepped by substituting her own scientific conclusions for the jury's role. The MDL now returns to Cote for resumed pretrial proceedings.
MDL Track
MDL 3043
S.D.N.Y.
Acetaminophen ASD/ADHD products liability
58 pending
State Court Activity
Active independent litigation in NY, DE, CA, MO, PA; Texas AG enforcement action filed October 2025 in Panola County against J&J and Kenvue alleging fraudulent transfer and DTPA violations
MDL 3043 Leadership
Plaintiff Leadership
Plaintiffs' Co-Lead Counsel
Plaintiffs' Liaison Counsel
Plaintiffs' Executive Committee
Law & Briefing Committee Chair
Early Vetting/Bellwether Selection Committee Chair
Discovery/ESI Committee Chair
Science & Expert Committee Chair
Settlement/Lien Resolution Committee Chair
Plaintiffs' Steering Committee
Defense Leadership
Defense Liaison Counsel
Retailer Liaison Committee
Manufacturer Liaison
Geographic exposure
Approximately 65% of pregnant women nationally used acetaminophen during pregnancy per cited epidemiological data; estimated tens of billions in potential damages per Texas AG complaint. MDL 3043 collapse shifts litigation to state courts and AG enforcement actions. Retailer defendants: CVS, Costco, Walgreens, Rite Aid, Safeway, Target, Walmart, Family Dollar, Dollar Tree.
State AG enforcement action filed October 27, 2025 in Panola County District Court (Texas v. Johnson & Johnson and Kenvue) alleging DTPA violations for deceptive marketing of acetaminophen to pregnant women; seeks monetary penalties exceeding $250,000 and marketing restrictions. Complaint cites ~65% prenatal usage rate nationally. Fraudulent transfer claim alleges J&J shed Tylenol liabilities to Kenvue in 2023 to evade exposure.
Bellwether plaintiff exposure: Denice Hayes purchased, used, treated, and died in Alabama from acute liver failure after taking Extra Strength Tylenol as directed. Terry v. McNeil-PPC, Inc., 2:12-cv-07263, designated bellwether in MDL 2436 (In re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation), E.D. Pa. before Judge Lawrence F. Stengel. Choice-of-law battleground: Alabama allows uncapped punitive damages; New Jersey precludes punitive damages in wrongful death actions and caps at 5x compensatory or $350,000.
J&J principal place of business (New Brunswick); McNeil Consumer Healthcare headquartered in Fort Washington, Pennsylvania but maintains nerve center in Skillman, New Jersey. State DEP suit filed October 2025 against J&J, Pfizer, Honeywell over Morris Plains pharmaceutical plant contamination. TCE groundwater contamination at 16,000 ppm (1989); 2012 CEA designation for aquifer along Tabor Road. Groundwater supplies >900 million gallons/day serving >50% of state population.
Proposed transferee district in JPML briefing for MDL 3043; Northern District of California supported by some plaintiffs. High volume acetaminophen sales, large birth cohorts 2000-2020. 2-year discovery rule SOL (Cal. Code Civ. Proc. § 335.1).
5-year SOL from discovery (Mo. Rev. Stat. § 516.120) — more lenient than most states. State court filings referenced in July 2026 reports.
MDL 2436 transferee court (E.D. Pa.); original filing venue for Terry bellwether. State court filings active post-MDL 3043 collapse. 2-year SOL from discovery (42 Pa. Cons. Stat. § 5524).
MDL 3043 transferee court (S.D.N.Y. before Senior Judge Denise L. Cote). Centralized October 5, 2022; 66 actions transferred from seven districts. April 2023: Cote denied J&J motion to dismiss on federal preemption. General causation experts later excluded under Daubert, collapsing MDL. 3-year SOL from injury.
Alternative transferee proposal in JPML briefing; Target Corporation headquartered in Minneapolis. Retailer defendant in MDL 3043.
Key defendants
Johnson & Johnson Consumer Inc.
Role: Manufacturer
Core manufacturer defendant in MDL 3043 (S.D.N.Y., Judge Cote). Survived motion to dismiss in Chapman v. Walmart, 22cv8830; court found Nevada failure-to-warn claims adequately pled. Preemption defense rejected in Nov. 2022 order. Currently facing general causation discovery and Daubert briefing.
Johnson & Johnson
Role: Parent/Former Manufacturer
Named in Texas AG suit (Panola County, filed Oct. 2025) for fraudulent transfer of Tylenol liabilities to Kenvue. Alleged to have known of ASD/ADHD risks. State seeks injunctive relief and penalties under Texas DTPA and UFTA.
Kenvue, Inc.
Role: Successor Manufacturer
Delaware successor entity that allegedly received fraudulent transfer of Tylenol liabilities from J&J. Named as defendant in Texas AG action. Principal place of business New Jersey; conducts business in Texas.
Kenvue Brands LLC
Role: Successor Manufacturer
f/k/a Johnson & Johnson Consumer Inc. Named alongside Kenvue, Inc. in Texas AG fraudulent transfer suit. Same litigation posture as Kenvue, Inc.—primary exposure is successor liability and UFTA claims.
Walmart, Inc.
Role: Retailer Defendant
Named retailer defendant in MDL 3043. Survived motion to dismiss in Chapman, 22cv8830. Court rejected argument that retailer lacked duty to warn. Currently in general causation discovery phase alongside other retailers.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Johnson & Johnson Consumer Inc. | Manufacturer | Core manufacturer defendant in MDL 3043 (S.D.N.Y., Judge Cote). Survived motion to dismiss in Chapman v. Walmart, 22cv8830; court found Nevada failure-to-warn claims adequately pled. Preemption defense rejected in Nov. 2022 order. Currently facing general causation discovery and Daubert briefing. |
| Johnson & Johnson | Parent/Former Manufacturer | Named in Texas AG suit (Panola County, filed Oct. 2025) for fraudulent transfer of Tylenol liabilities to Kenvue. Alleged to have known of ASD/ADHD risks. State seeks injunctive relief and penalties under Texas DTPA and UFTA. |
| Kenvue, Inc. | Successor Manufacturer | Delaware successor entity that allegedly received fraudulent transfer of Tylenol liabilities from J&J. Named as defendant in Texas AG action. Principal place of business New Jersey; conducts business in Texas. |
| Kenvue Brands LLC | Successor Manufacturer | f/k/a Johnson & Johnson Consumer Inc. Named alongside Kenvue, Inc. in Texas AG fraudulent transfer suit. Same litigation posture as Kenvue, Inc.—primary exposure is successor liability and UFTA claims. |
| Walmart, Inc. | Retailer Defendant | Named retailer defendant in MDL 3043. Survived motion to dismiss in Chapman, 22cv8830. Court rejected argument that retailer lacked duty to warn. Currently in general causation discovery phase alongside other retailers. |
Timeline
First Epidemiological Study Links Prenatal APAP to ADHD
JAMA Pediatrics publishes Danish cohort study (Liew et al.) finding association between prenatal acetaminophen use and increased ADHD-like behaviors in children. Marks beginning of scientific foundation for later litigation.
Nature Reviews Endocrinology Consensus Statement
Consensus statement signed by 91 scientists and clinicians published in Nature Reviews Endocrinology calls for precautionary approach to prenatal acetaminophen use, citing neurodevelopmental risks.
JPML Creates MDL 3043 in S.D.N.Y.
Judicial Panel on Multidistrict Litigation transfers approximately 66 lawsuits to Senior District Judge Denise Cote in the Southern District of New York, creating MDL No. 3043, In re: Acetaminophen – ASD-ADHD Products Liability Litigation.
Judge Cote Rejects Preemption Defenses
Judge Denise Cote denies motions to dismiss on preemption grounds, allowing state-law failure-to-warn claims to proceed against Johnson & Johnson and retailers. In re Acetaminophen – ASD-ADHD Prods. Liab. Litig., No. 22md3043 (DLC), 2022 WL 17348351 (S.D.N.Y. Nov. 14, 2022).
Judge Cote Dismisses Federal MDL Cases
Judge Cote issues 148-page opinion excluding all five plaintiffs' general causation experts under Daubert and granting summary judgment, effectively terminating MDL 3043. In re Acetaminophen – ASD-ADHD Prods. Liab. Litig., No. 22md3043 (DLC) (S.D.N.Y. Dec. 18, 2023).
Judge Cote Excludes Replacement Expert
Judge Cote excludes replacement expert Dr. Roberta Ness under Daubert, closing remaining path to revive general causation in MDL 3043.
Plaintiffs Appeal to Second Circuit
Plaintiffs file appeal to Second Circuit Court of Appeals challenging Judge Cote's Daubert exclusions and summary judgment. Case No. 25-307.
MDL Administratively Reopened
MDL 3043 administratively reopened to accept six tag-along cases but remains dormant pending appellate resolution.
FDA Initiates Label Change Process
FDA announces initiation of label change for acetaminophen products to reflect evidence of possible association between prenatal use and autism/ADHD in children. Agency issues physician notifications.
Second Circuit Hears Oral Arguments
Second Circuit Court of Appeals hears oral arguments in Case No. 25-307. Panel questions whether Judge Cote was overly aggressive in expert exclusions. Decision pending as of June 2026.
Statute of limitations
Federal preemption defenses rejected in MDL 22-3043 per Judge Cote's rulings, but general causation Daubert standard presents threshold barrier. Minor tolling varies by state; intake must verify date of majority and discovery timing. No active revival statutes identified as of March 2026.
New York
3 years from discovery
Rule: CPLR § 214(2) products liability; discovery rule applies for latent injuries
Discovery: Accrues when injury is discovered or should have been discovered through reasonable diligence; for minors, tolling until age 18 plus 3 years
MDL 22-3043 (Cote, J.) reopened Nov. 12, 2024 after closure Aug. 26, 2024; new filings accepted. Daubert hearing completed Dec. 2023; general causation experts largely excluded per Dec. 18, 2023 order (Dkt. 1381). Intake viable but causation hurdles remain.
California
2 years from discovery
Rule: Cal. Code Civ. Proc. § 335.1; discovery rule applies per Jolly v. Eli Lilly & Co., 751 P.2d 923 (Cal. 1988)
Discovery: Accrues when plaintiff knows or should know of injury and its probable cause; minor tolling until age 18
No revival statute active. Significant plaintiff pool given birth cohort exposure data.
Texas
2 years from discovery
Rule: Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies
Discovery: Accrues when injury becomes inherently undiscoverable and objectively apparent to reasonable person
Judge Cote dismissed Texas-law complaints without prejudice due to Texas statutory 'safe harbor' preemption for retailers (Tex. Civ. Prac. & Rem. Code § 82.007). J&J claims remain viable but retailer claims face preemption barrier.
⚠Florida
2 years from discovery
Rule: Fla. Stat. § 95.11(3)(a), (e); reduced from 4 years effective March 24, 2023 (HB 837)
Discovery: Accrues when facts giving rise to cause of action are discovered or should have been discovered
Legislative reduction from 4 to 2 years applies prospectively; transitional claims may exist. No minor tolling beyond age 18.
Pennsylvania
2 years from discovery
Rule: 42 Pa. Cons. Stat. § 5524(2); discovery rule applies
Discovery: Accrues when plaintiff knows or reasonably should know of injury and its cause; minor tolling until age 18
No revival statute. Large birth cohort in Philadelphia metro area.
Ohio
2 years from discovery
Rule: Ohio Rev. Code § 2305.10(C); discovery rule applies
Discovery: Accrues when injury is discovered or should have been discovered with reasonable diligence; minor tolling until age 18 plus 2 years
No revival statute pending.
Illinois
2 years from discovery
Rule: 735 ILCS 5/13-202; discovery rule applies per Knox College v. Celotex Corp., 574 N.E.2d 677 (Ill. 1991)
Discovery: Accrues when injury and its wrongful cause are discovered or should have been discovered; minor tolling until age 18 plus 2 years
No revival statute. Centralized birth records support exposure documentation.
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| New York | 3 years from discovery | CPLR § 214(2) products liability; discovery rule applies for latent injuries | Accrues when injury is discovered or should have been discovered through reasonable diligence; for minors, tolling until age 18 plus 3 years | MDL 22-3043 (Cote, J.) reopened Nov. 12, 2024 after closure Aug. 26, 2024; new filings accepted. Daubert hearing completed Dec. 2023; general causation experts largely excluded per Dec. 18, 2023 order (Dkt. 1381). Intake viable but causation hurdles remain. |
| California | 2 years from discovery | Cal. Code Civ. Proc. § 335.1; discovery rule applies per Jolly v. Eli Lilly & Co., 751 P.2d 923 (Cal. 1988) | Accrues when plaintiff knows or should know of injury and its probable cause; minor tolling until age 18 | No revival statute active. Significant plaintiff pool given birth cohort exposure data. |
| Texas | 2 years from discovery | Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies | Accrues when injury becomes inherently undiscoverable and objectively apparent to reasonable person | Judge Cote dismissed Texas-law complaints without prejudice due to Texas statutory 'safe harbor' preemption for retailers (Tex. Civ. Prac. & Rem. Code § 82.007). J&J claims remain viable but retailer claims face preemption barrier. |
| ⚠Florida | 2 years from discovery | Fla. Stat. § 95.11(3)(a), (e); reduced from 4 years effective March 24, 2023 (HB 837) | Accrues when facts giving rise to cause of action are discovered or should have been discovered | Legislative reduction from 4 to 2 years applies prospectively; transitional claims may exist. No minor tolling beyond age 18. |
| Pennsylvania | 2 years from discovery | 42 Pa. Cons. Stat. § 5524(2); discovery rule applies | Accrues when plaintiff knows or reasonably should know of injury and its cause; minor tolling until age 18 | No revival statute. Large birth cohort in Philadelphia metro area. |
| Ohio | 2 years from discovery | Ohio Rev. Code § 2305.10(C); discovery rule applies | Accrues when injury is discovered or should have been discovered with reasonable diligence; minor tolling until age 18 plus 2 years | No revival statute pending. |
| Illinois | 2 years from discovery | 735 ILCS 5/13-202; discovery rule applies per Knox College v. Celotex Corp., 574 N.E.2d 677 (Ill. 1991) | Accrues when injury and its wrongful cause are discovered or should have been discovered; minor tolling until age 18 plus 2 years | No revival statute. Centralized birth records support exposure documentation. |
Live intelligence
AI litigation brief
Tylenol / APAP remains active mdl with 108 current signals in the accepted feed.
Overview
The Second Circuit reversed Judge Denise Cote's Daubert exclusion of three plaintiff general causation experts on July 13, 2026, reviving MDL 3043 (In re: Acetaminophen ASD/ADHD Products Liability Litigation, 1:22-md-03043) in the S.D.N.Y. Judge Guido Calabresi's 64-page opinion held Cote overstepped by substituting her own scientific conclusions for the jury's role. The MDL now returns to Cote for resumed pretrial proceedings.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 3043, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 3043 should stay on the lead docket watch because it is the primary consolidation vehicle for Tylenol.
Generated Aug 12, 2026, 2:00 AM UTC
108 events detected
Google News (47)
Tylenol Autism & ADHD Lawsuit September, 11 2023 Update Keith Law Group Weather Hamilton (24qqnJgNgP) - Mshale
Ashley Keller Appeals Sanctions in Acetaminophen Cases, Asks to Reassign MDL to Another Judge - Law.com
Should You Stop Taking Tylenol During Pregnancy After the Lawsuit News? Here's What Doctors Want You to Know - Medical Daily
Opinion | Tylenol lawsuits are asking the wrong question about use in pregnancy - The Washington Post
Carlson Law Firm Accepting Clients After Appeals Court Allows Tylenol Lawsuits to Proceed - PR Newswire
Appeals Court Revives 500-Plus Tylenol Autism Lawsuits: What Pregnant Women Should Know About the Evidence - Medical Daily
How To File A Claim | Tylenol Autism Lawsuit Patrick Roy (VSyzfVkeT9) - Mshale
Pres. Trump ties autism to over-the-counter drug - FOX 13 Tampa Bay
Court revives lawsuits linking Tylenol use in pregnancy to autism, ADHD - The San Joaquin Valley Sun
2nd Circuit revives hundreds of suits linking Tylenol to autism - Michigan Lawyers Weekly
Appeals court revives Tylenol autism and ADHD lawsuits - MSN
US appeals court reverses dismissal of Tylenol cases - Jurist.org
Appeals court revives lawsuit against Tylenol brought by parents of children with autism - Denver Gazette
Tylenol-Autism Lawsuits Get New Life In Federal Court - cheddar.com
Appeals court revives Tylenol autism lawsuits against Kenvue - MSN
GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits - MedPage Today
Private Lawsuits Linking Tylenol To Autism Revived - Talk 650 KSTE
Health Brief: Tylenol lawsuits roar back - The Washington Post
Appeals court restores over 500 lawsuits alleging Tylenol linked to autism - Межа. Новини України.
US Appeals Court Revives Over 500 Tylenol Lawsuits Over Autism Claims - Health and Me
US appeals court revives hundreds of private lawsuits linking Tylenol to autism - ETPharma.com
US Appeals Court Revives Over 500 Lawsuits Linking "Tylenol" to Autism - صوت الإمارات
Judges allow lawsuit that ties Tylenol to autism to continue after it was dismissed for lack of ‘scientific evidence’ - AOL.com
Appeals court revives lawsuits claiming link between acetaminophen, ADHD and autism - The Hill
US appeals court revives hundreds of lawsuits linking Tylenol to autism - The Independent
Court Revives Lawsuits Tying Tylenol Use in Pregnancy to Autism and ADHD - GV Wire
Appeals Court Revives Private Lawsuits Linking Tylenol to Autism - Insurance Journal
Appeals Court Revives Lawsuits Tying Tylenol Use in Pregnancy to Autism and A.D.H.D. - The New York Times
Appeals court revives Tylenol autism, ADHD lawsuits - MSN
Tylenol Lawsuit Gets New Life, Shaking Kenvue Shares - Finimize
Kenvue's Tylenol Liability Nightmare: Appeals Court Reversal Ignites Fresh Legal Battle - Kavout | AI
Appeals Court Revives Lawsuits Alleging Tylenol Causes Autism and ADHD - WSJ
US appeals court revives private lawsuits linking Tylenol to autism - MSN
US appeals court revives private cases alleging Tylenol link to autism - France 24
KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits - Stocktwits
Tylenol-Maker Kenvue Must Face Autism Lawsuits, Court Says (2) - Bloomberg Law News
US appeals court revives private lawsuits linking Tylenol to autism, ADHD - Classic Rock 103.5 WIMZ
US court revives 550 Tylenol lawsuits over autism claims - MSN
US Appeals court revives lawsuits linking Tylenol-maker Kenvue to autism (update) (KVUE:NYSE) - Seeking Alpha
Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says - Bloomberg.com
J&J, Kenvue, Sued Over Autism by Texas, Look to Lack State Ties - Bloomberg Law News
Birth Defect Lawsuit in 2026: Payouts, Eligibility - LawFold.com
New medical guidance affirms Tylenol safety during pregnancy months after Trump sows doubt - Stateline
Harvard Tylenol Lawsuit: 2026 Case Updates, Payouts - LawFold.com
Texas AG Blocks Kenvue Dividend Over Tylenol Autism Lawsuit Scandal Keaton Wagler (VepgInOB6D) - Mshale
Keller Postman Tylenol Lawsuit Update 2026: Full Guide - LawFold.com
What we know about Tylenol and autism, as Texas AG Ken Paxton files suit - MSN
JAMA • Anderer S • PMID 42430144 • Journal Article.
JAMA pediatrics • Grabowski MK • PMID 42545713 • Journal Article.
Birth defects research • Arena AC • PMID 42543224 • Journal Article.
Experimental & molecular medicine • Chen L • PMID 42509303 • Journal Article.
Journal of animal science • Wright CJ • PMID 42489539 • Journal Article.
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket filed in JPML: The plaintiffs, represented by a mother on behalf of her minor children, are suing a major manufacturer and various retailers for distributing defective over-the-counter medications, specifically acetaminophen-based products like Tylenol. The lawsuit claims that using these medications during pregna
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33250285)Document filed by Linda Sexton, Dale Sexton..(Evola, Robert) (Entered: 08/06/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer, Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33249966)Document filed by Amy Lambert, Jayden Lambert..(Evola, Robert) (Entered: 08/06/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33247977)Document filed by Daniel Barreto..(Buchanan, David) (Entered: 08/05/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer, Inc., Walgreen Co.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33241934)Document filed by Laura Fennewald, L.F., a Minor, N.F., a Minor..(Evola, Robert) (Entered: 08/04/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson, Johnson & Johnson Consumer, Inc., Kenvue, Inc., Walgreen Co.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33232617)Document filed by Dazzline Montoya, G.R., a Minor..(Evola, Robert) (Entered: 08/03/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against CVS Pharmacy, Inc., Johnson & Johnson, Johnson & Johnson Consumer, Inc., Kenvue, Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33232314)Document filed by Marilyn Velazquez, F. V., a Minor..(Evola, Robert) (Entered: 08/03/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson, Johnson & Johnson Consumer Inc., Kenvue, Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33232034)Document filed by Michele Richards, Thomas Hayden..(Evola, Robert) (Entered: 08/03/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against CVS Pharmacy, Inc., Johnson & Johnson, Johnson & Johnson Consumer Inc, Kenvue, Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33231634)Document filed by Vanessa Ward, Briana Waller..(Evola, Robert) (Entered: 08/03/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer, Inc., Johnson & Johnson Inc., Kenvue Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33225615)Document filed by Chantel Wessel, Elijah Simon..(Evola, Robert) (Entered: 07/31/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
92Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Aug 12, 2026, 2:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
FAERS
PubMed
Event feed
108
events detected
AI Brief
Tylenol / APAP remains active mdl with 108 current signals in the accepted feed.
Overview
The Second Circuit reversed Judge Denise Cote's Daubert exclusion of three plaintiff general causation experts on July 13, 2026, reviving MDL 3043 (In re: Acetaminophen ASD/ADHD Products Liability Litigation, 1:22-md-03043) in the S.D.N.Y. Judge Guido Calabresi's 64-page opinion held Cote overstepped by substituting her own scientific conclusions for the jury's role. The MDL now returns to Cote for resumed pretrial proceedings.
Key developments
PACER court filing on Dec 31: Acetaminophen - ASD/ADHD Products Liability Litigation. ‖ Mshale news on Aug 11: Tylenol Autism & ADHD Lawsuit September, 11 2023 Update Keith Law Group Weather Hamilton (24qqnJgNgP) - Mshale. ‖ FAERS FDA alert on Jun 30: FAERS Filing 26940163: Autism spectrum disorder. ‖ PubMed research on Aug 4: Acetaminophen Use During Pregnancy Is Unlikely to Cause Autism or ADHD, New Study Reaffirms..
Generated Aug 12, 2026, 2:00 AM UTC
Tracked MDLs
MDL 3043
S.D.N.Y.
Acetaminophen ASD/ADHD products liability